Literature DB >> 20876083

RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.

Anthony J Bell1, David Fegen, Maureen Ward, Arthur Bank.   

Abstract

Lentiviral vectors derived from the HIV-1 genome offer great promise for gene therapy due to their ability to transduce non-dividing cells and sustain long-term expression of transgenes. The majority of current lentiviral vectors are pseudotyped with the vesicular stomatitis viral envelope (VSV-G). VSV-G equips lentiviral vectors with a broad host cell tropism and increased stability. Increased particle stability enables viral supernatants to be concentrated by high-speed centrifugation to enhance their infectivity. Despite its efficacy, VSV-G is cytotoxic - a feature that prohibits the development of stable cell lines that constitutively express this envelope. Therefore, non-toxic envelope proteins are being investigated. RD114 is an attractive alternative because it also provides increased particle stability and its receptor is widely expressed on hematopoietic stem cells (HSCs). In this study, the packaging efficiency of three envelope proteins, RD114, RDpro and VSV-G, were evaluated with two lentiviral vectors (TRIP GFP and HPV-402). RDpro is an RD114-HIV chimera designed to pseudotype lentiviral vectors more efficiently. In transient systems, VSV-G generated titers of 10(8) and 10(7) viral particles/mL for TRIP GFP and HPV-402. RDpro possessed titers of 10(7) and 10(6), while RD114 titers were one log lower for each vector. Despite having relatively lower titers, RD114 proteins are less toxic; this was demonstrated in the extension of transient transfection reactions from 48 to 96 h. VSV-G transfections are generally limited to 48 h. In regard to gene therapy applications, we show that RDpro supernatants efficiently transduce peripheral blood HSCs. The versatility of RD114 envelopes was again demonstrated by using a 'mixed' expression system; composed of stably expressed RD114 envelope proteins to pseudotype lentiviral vectors generated in trans (titer range 10(3)-10(5)). Our data show that RD114 envelope proteins are effective and versatile constructs that could prove to be essential components of therapeutic lentiviral gene transfer systems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876083     DOI: 10.1258/ebm.2010.010053

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  11 in total

1.  CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.

Authors:  Sarah-Katharina Kays; Kerstin B Kaufmann; Tobias Abel; Christian Brendel; Halvard Bonig; Manuel Grez; Christian J Buchholz; Sabrina Kneissl
Journal:  Stem Cells Dev       Date:  2015-01-20       Impact factor: 3.272

Review 2.  Direct reprogramming of mouse fibroblasts into cardiac myocytes.

Authors:  Kohei Inagawa; Masaki Ieda
Journal:  J Cardiovasc Transl Res       Date:  2012-10-03       Impact factor: 4.132

3.  Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy.

Authors:  Kismet Baldwin; Fabrizia Urbinati; Zulema Romero; Beatriz Campo-Fernandez; Michael L Kaufman; Aaron R Cooper; Katelyn Masiuk; Roger P Hollis; Donald B Kohn
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

4.  CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.

Authors:  Christian Brendel; Benjamin Goebel; Abriss Daniela; Martijn Brugman; Sabrina Kneissl; Joachim Schwäble; Kerstin B Kaufmann; Uta Müller-Kuller; Hana Kunkel; Linping Chen-Wichmann; Tobias Abel; Hubert Serve; Leonid Bystrykh; Christian J Buchholz; Manuel Grez
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

5.  Mass spectrometry analysis reveals differences in the host cell protein species found in pseudotyped lentiviral vectors.

Authors:  Sabine Johnson; Jun X Wheeler; Robin Thorpe; Mary Collins; Yasuhiro Takeuchi; Yuan Zhao
Journal:  Biologicals       Date:  2018-02-01       Impact factor: 1.856

Review 6.  Lentiviral Vector Bioprocessing.

Authors:  Christopher Perry; Andrea C M E Rayat
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

7.  Construction of stable packaging cell lines for clinical lentiviral vector production.

Authors:  Khaled S Sanber; Sean B Knight; Sam L Stephen; Ranbir Bailey; David Escors; Jeremy Minshull; Giorgia Santilli; Adrian J Thrasher; Mary K Collins; Yasuhiro Takeuchi
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

Review 8.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13

9.  RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

Authors:  Virna Marin; Anna Stornaiuolo; Claudia Piovan; Stefano Corna; Sergio Bossi; Monika Pema; Erica Giuliani; Cinzia Scavullo; Eleonora Zucchelli; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2016-05-11       Impact factor: 6.698

Review 10.  Current status on the development of pseudoviruses for enveloped viruses.

Authors:  Qianqian Li; Qiang Liu; Weijin Huang; Xuguang Li; Youchun Wang
Journal:  Rev Med Virol       Date:  2017-12-07       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.